Is Aardvark Therapeutics, Inc. Common Stock (AARD) a Buy, Sell, or Hold?
NASDAQ : AARD
Aardvark Therapeutics, Inc. Common Stock
$6.33 USD
-$0.34 (-5.1%)
- Volume
- 4.1K
- Average Volume
- 270.89K
- Market Capitalization
- $138.53M
- P/E Ratio
- -2.05
- Dividend Yield
- 0.00%
- Price Target
- $4.50
- Year High
- $17.94
- Year Low
- $3.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.06
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Tien-Li Lee |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AARD |
| CUSIP | 002942100 |
| CIK | 0001774857 |
| Web | https://aardvarktherapeutics.com |
| Phone | 858 225 7696 |
| Currency | USD |
| Employees | 40 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.06 |
| Quick Ratio | 8.06 |
| Cash Ratio | 5.38 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -2.83 |
| Price / Cash Flow | -2.33 |
| Price / Book | 1.65 |
Price Target and Rating
| Average Stock Price Forecast | $4.50 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | 40.67% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$2.64 |
| Trailing P/E Ratio | -2.05 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | -$57.59M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -61.71% |
| Return on Assets | -70.87% |
Financials Score
| AltmanZ Score | 3.61 |
| Piotroski Score | 1.00 |
| Working Capital | 81.98M |
| Total Assets | 98.59M |
| Ebit | -69.87M |
| Market Cap | 133.52M |
| Total Liabilities | 11.6M |
Poll Results
About Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) Stock
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surge ... ry or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
2026-06-25 09:00:00
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.
2026-06-19 10:00:00
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire
2026-06-19 09:00:00
SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.
2026-06-11 10:00:00
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-09 13:45:00
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-02 17:02:00
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-02 16:30:00
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome (“PWS”). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.
2026-05-28 10:00:00
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Aardvark Therapeutics, Inc. Common Stock (AARD) stock price?
-
Aardvark Therapeutics, Inc. Common Stock(NASDAQ:AARD) stock price is $6.33 in the last trading session. During the trading session, AARD stock reached the peak price of $17.94 while $3.35 was the lowest point it dropped to. The percentage change in AARD stock occurred in the recent session was --5.1% while the dollar amount for the price change in AARD stock was -$0.34.
-
AARD's industry and sector of operation?
-
The NASDAQ listed AARD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AARD?
-
Zhenhuan Zheng | Chief Research Officer
Derrick C. Li | Chief Business Officer
Nelson Sun | CFO & COO
Ron Lewis | Vice President & Head of CMC
Danny Villeneuve | Chief Commercial Officer -
How many employees does AARD have?
-
Number of AARD employees currently stands at 40. AARD operates from 4370 La Jolla Village Drive, San Diego, CA 92122, US.
-
Link for AARD official website?
-
Official Website of AARD is: https://aardvarktherapeutics.com
-
How do I contact AARD?
-
AARD could be contacted at phone #858 225 7696 and can also be accessed through its website. AARD operates from 4370 La Jolla Village Drive, San Diego, CA 92122, US.
-
How many shares of AARD are traded daily?
-
The average number of AARD shares traded daily for last 3 months was 270.89K.
-
What is the market cap of AARD currently?
-
The market value of AARD currently stands at $138.53M with its latest stock price at $6.33